Stocks Health care EPRX
NASDAQ · Health careEupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. reported revenue of $0 in fiscal 2025. It posted a net loss of $38.6M. At December 31, 2025 it held $80.6M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 13, 2026.
Key facts about Eupraxia Pharmaceuticals Inc.
- Net worth
- Eupraxia Pharmaceuticals Inc. has a market value (market cap) of $489M at the latest share price, and shareholders' equity of $82M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $38.6M.
- Cash flow
- In fiscal 2025 operations used $28.6M of cash.
- Latest report
- The latest periodic report (annual report (Canadian issuer), 40-F) was filed with the SEC on March 13, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Eupraxia Pharmaceuticals Inc. does
Eupraxia Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EPRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$38.6M | -$1.03 | n/a |
| 2024 | $0 | -$25.5M | -$0.76 | n/a |
| 2023 | $0 | -$28.2M | -$1.17 | n/a |
| 2023 | n/a | -$18.5M | -$0.96 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Eupraxia Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 22, 2026
- October 15, 2026
- October 9, 2026
- September 30, 2026
- September 8, 2026
- September 2, 2026Form SUPPL filing SUPPL
- August 19, 2026Form F-10/A filing F-10/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 11, 2026
Insider trades
What the people running Eupraxia Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns EPRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Joseph S. Freedman13D, may seek influence | 9% | March 16, 2026 |
| Beutel, Goodman & Co Ltd.13G, passive | 8% | November 14, 2025 |
| Robert Disbrow13G, passive | 7% | November 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 68 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Affinity Asset Advisors, LLC | 1,650,000 | +60,995 |
| Balyasny Asset Management L.P. | 1,350,015 | +15 |
| Vivo Capital, LLC | 1,350,000 | 0 |
| Scotia Capital Inc. | 1,343,726 | +1,548 |
| PFM Health Sciences, LP | 1,210,661 | +669,790 |
| Great Point Partners LLC | 1,200,000 | 0 |
| Jupiter Topco LLC | 1,046,000 | new |
| Rubric Capital Management LP | 867,424 | +176,254 |
| Ikarian Capital, LLC | 809,741 | -405,000 |
| Woodline Partners LP | 746,864 | +306,313 |
| Point72 Asset Management, L.P. | 730,284 | -237,291 |
| Ameriprise Financial Inc | 711,024 | +61,950 |
| Redmile Group, LLC | 611,400 | -88,600 |
| Seven Fleet Capital Management LP | 610,785 | +177,270 |
| UBS Group AG | 519,211 | -243,424 |
| Citadel Advisors LLC | 502,011 | +271,835 |
| Millennium Management LLC | 441,586 | new |
| Alyeska Investment Group, L.P. | 375,000 | 0 |
| Picton Mahoney Asset Management | 360,878 | new |
| Velan Capital Investment Management LP | 352,000 | 0 |
Insiders
Questions about EPRX
What does Eupraxia Pharmaceuticals Inc. do?
Eupraxia Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as EPRX. Its shares trade on NASDAQ under the ticker EPRX.
What is Eupraxia Pharmaceuticals Inc.'s net worth?
Eupraxia Pharmaceuticals Inc. has a market value (market cap) of $489M at the latest share price, and shareholders' equity of $82M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Eupraxia Pharmaceuticals Inc. profitable?
No. In fiscal 2025 it reported a net loss of $38.6M.
How much revenue does Eupraxia Pharmaceuticals Inc. make?
In fiscal 2025 Eupraxia Pharmaceuticals Inc. reported revenue of $0.
When did Eupraxia Pharmaceuticals Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 13, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 22, 2026.
Similar companies
Compare EPRX with
Follow EPRX
Get an email when Eupraxia Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Eupraxia Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.